Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 3;18(13):1513–1522. doi: 10.1080/15384101.2019.1624113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Informa UK Limited, trading as Taylor & Francis Group

PMC Copyright notice

Figure 5. — Neratinib combination with MEK or PI3K inhibitors induces synergistic growth inhibition in HER2-L755S mutant cells. (a) Cell proliferation of HER2-L755S treated with neratinib (100nM), AZD6244 (1uM), or in combination as indicated. Representative data are expressed as log2-fold change normalized to day 0 of three technical replicates. (b) Cell proliferation of HER2-L755S treated with neratinib (100nM), GDC0941 (1uM), or in combination as indicated. Representative data are expressed as log2-fold change normalized to day 0 of three technical replicates. (c) Western blotting showing the expression of HER2, EGFR, AKT, p70S6K, MEK1/2 and p42/44 MAPK in MCF10A bearing HER2-L755S treated with MEK inhibitor neratinib (30nM) and AZD6244 (1uM) (left) or PI3K inhibitor GDC0941 (1uM) for 4 h (right).